omniture
CSTONE PHARMACEUTICALS

Latest News

CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL

SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- CStone Pharmaceuticals (SUZHOU) Co., Ltd. ("CStone", H...

2020-08-31 11:35 2461

CStone Pharmaceuticals Reports Financial Results for the First Half of 2020

SUZHOU, China, Aug. 19, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leadi...

2020-08-19 09:33 3152

CStone submits new drug application for the targeted therapy avapritinib in Taiwan for the treatment of adults with advanced PDGFRA exon 18 mutant gastrointestinal stromal tumor

SUZHOU, China, March 27, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2020-03-27 14:02 985

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

SUZHOU, China, Jan. 24, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2020-01-24 14:26 2111

CStone successfully hosted the first U.S. R&D Day in New York

* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical de...

2020-01-24 08:18 2465

CStone successfully hosted the first U.S. R&D Day in New York

* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical de...

2020-01-24 08:03 1845

CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma

SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX...

2020-01-08 13:45 1776

CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia

SUZHOU, China, Dec. 12, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-12-12 14:47 1698

CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST

SUZHOU, China, Dec. 11, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-12-11 11:00 1570

CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial

SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX...

2019-12-06 18:53 1937

CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib

SUZHOU, China, Nov. 20, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-11-20 11:41 1025

ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma

SUZHOU, China, Nov. 7, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX...

2019-11-07 11:02 997

ESMO 2019: CStone presents pooled safety data from the Phase 1b trial of CS1001, demonstrating promising overall safety and tolerability

SUZHOU, China, Sept. 30, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2019-09-30 18:29 1011

2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors

SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2019-09-22 14:22 1262

2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab

SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2019-09-22 13:39 1412

2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors

SUZHOU, China, Sept. 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2019-09-21 00:26 1536

2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%

SUZHOU, China, Sept. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2019-09-19 23:48 1614

CStone announces first patient dosed in China for Phase I/II registrational bridging trial of avapritinib in advanced GIST

SUZHOU, China, Aug. 26, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today an...

2019-08-26 11:21 1932

CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting

SUZHOU, China, Aug. 23, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-08-23 11:26 2239
12345